APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 3, 2014, Pages

  Lan, Xiqian ^a   Jhaveri, Aakash ^a   Cheng, Kang ^a   Wen, Hongxiu ^a   Saleem, Moin A ^b   Mathieson, Peter W ^b   Mikulak, Joanna ^c   Aviram, Sharon ^d   Malhotra, Ashwani ^a   Skorecki, Karl ^d   Singhal, Pravin C ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

APOL1 risk variants; Kidney disease; Lysosomal membrane permeability; Necrosis; Podocyte

Indexed keywords

4,4' DIISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; APOLIPOPROTEIN; APOLIPOPROTEIN L1; CATHEPSIN L; CHLORIDE; CHLOROQUINE; HYDROGEN PEROXIDE; PUROMYCIN AMINONUCLEOSIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; GENE EXPRESSION SYSTEM; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXIA; KIDNEY DISEASE; LENTIVIRINAE; LYSOSOME; LYSOSOME MEMBRANE; PODOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; WILD TYPE;

APOL1 RISK VARIANTS; KIDNEY DISEASE; LYSOSOMAL MEMBRANE PERMEABILITY; NECROSIS; PODOCYTE;

4,4'-DIISOTHIOCYANOSTILBENE-2,2'-DISULFONIC ACID; ACTINS; AFRICAN AMERICANS; APOLIPOPROTEINS; CELLS, CULTURED; CHLORIDE CHANNELS; CHLOROQUINE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; LIPOPROTEINS, HDL; LYSOSOMES; NECROSIS; PERMEABILITY; PODOCYTES;

EID: 84905223337     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00647.2013     Document Type: Article

References (49)

1. Artal-Sanz M, Samara C, Syntichaki P, Tavernarakis N. Lysosomal biogenesis and function is critical for necrotic cell death in Caenorhabditis elegans. J Cell Biol 173: 231-239, 2006.
2. Atta MG. Diagnosis and natural history of HIV-associated nephropathy. Adv Chronic Kidney Dis 17: 52-58, 2010.
3. Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z, Wasser WG, Shenhar Y, Shahar E, Hassoun G, Maor C, Wolday D, Pollack S, Skorecki K. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol 34: 452-459, 2011.
4. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, Ojcius DM, Jäättelä M, Kroemer G. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med 197: 1323-1334, 2003.
5. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene 27: 6434-6451, 2008.
6. Castro J, Bittner CX, Humeres A, Montecinos VP, Vera JC, Barros LF. A cytosolic source of calcium unveiled by hydrogen peroxide with relevance for epithelial cell death. Cell Death Differ 11: 468-478, 2004.
7. Chandel N, Sharma B, Husain M, Salhan D, Singh T, Rai P, Mathieson PW, Saleem MA, Malhotra A, Singhal PC. HIV compromises integrity of the podocyte actin cytoskeleton through downregulation of the vitamin D receptor. Am J Physiol Renal Physiol 304: F1347-F1357, 2013.
8. Duchateau PN, Pullinger CR, Cho MH, Eng C, Kane JP. Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res Lipid Res 42: 620-630, 2001.
9. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, O'Connor PM, Malloy MJ, Kane JP. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 272: 25576-25582, 1997.
10. Dunham I, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burges J, Burrill WD, Burton J, Carder C, Carter NP, Che Y, Clark G, Clegg SM, Cobley V, Cole CG, Collier RE, Connor RE, Conroy D, Corby N, Coville GJ, Cox AV, Davis J, Dawson E, Dhami PD, Dockree C, Dodsworth SJ, Durbin RM, Ellington A, Evans KL, Fey JM, Fleming K, French L, Garner AA, Gilbert JGR, Goward ME, Grafham D, Griffiths MN, Hall C, Hall R, Hall-Tamlyn G, Heathcott RW, Ho S, Holmes S, Hunt SE, Jones MC, Kershaw J, Kimberley A, King A, Laird GK, Langford CF, Leversha MA, Lloyd C, Lloyd DM, Martyn ID, Mashreghi-Mohammad M, Matthews L, McCann OT, McClay J, McLaren S, McMurray AA, Milne SA, Mortimore BJ, Odell CN, Pavit R, Pearce AV, Pearson D, Phillimore BJ, Phillips SH, Plumb RW, Ramsay H, Ramsey Y, Rogers L, Ross MT, Scott CE, Sehra HK, Skuce CD, Smalley S, Smith ML, Soderlund C, Spragon L, Steward C, Sulston JE, Swann RM, Vaudin M, Wall M, Wallis JM, Whiteley MN, Willey D, Williams L, Williams S, Williamson H, Wilmer TE, Wilming L, Wright CL, Hubbard T, Bentley DR, Beck S, Rogers J, Shimizu N, Minoshima S, Kawasaki K, Sasaki T, Asakawa S, Kudoh J, Shintan A, Shibuya K, Yoshizaki Y, Aoki N, Mitsuyam S, Roe BA, Chen F, Chu L, Crabtree J, Deschamps S, Do A, Do T, Dorman A, Fang F, Fu Y, Hu P, Hua A, Kenton S, Lai H, Lao HI, Lewis J, Lewis S, Lin SP, Loh P, Malaj E, Nguyen T, Pan H, Phan S, Qi S, Qian Y, Ray L, Ren Shaull S, Sloan D, Song L, Wang Q, Wang Y, Wang Z, White J, Willingham D, Wu H, Yao Z, Zhan M, Zhang G, Chissoe S, Murra J, Miller N, Min P, Fulton R, Johnson D, Bemis G, Bentley D, Bradshaw H, Bourne S, Cordes M, Du Z, Fulto L, Goela D, Graves T, Hawkins J, Hinds K, Kemp K, Latreille P, Layman D, Ozersky P, Rohlfing T, Scheet C, Walke C, Wamsley A, Wohldmann P, Pepin K, Nelson J, Korf I, Bedell JA, Hillier L, Mardis E, Waterston R, Wilson R, Emanuel BS, Shaikh T, Kurahashi H, Saitta S, Budarf ML, McDermid HE, Johnson A, Wong ACC, Morrow BE, Edelmann L, Kim UJ, Shizuy H, Simon MI, Dumanski JP, Peyrard M, Kedra D, Seroussi E, Fransson I, Tapia I, Bruder CE, O'Brien KP. The DNA sequence of human chromosome 22. Nature 402: 489-495, 1999.
11. Fine DM, Wasser WG, Estrella MM, Atta MG, Kuperman M, Shemer R, Rajasekaran A, Tzur S, Racusen LC, Skorecki K. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol 23: 343-350, 2012.
12. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24: 1484-1491, 2013.
13. Freedman BI, Langefeld CD, Turner J, Núñez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int 82: 805-811, 2012.
14. Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 34: 254-258, 1999.
15. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Populationbased risk assessment of APOL1 on renal disease. J Am Soc Nephrol 22: 2098-2105, 2011.
16. Fukuda A, Wickman LT, Venkatareddy MP, Sato Y, Chowdhury MA, Wang SQ, Shedden KA, Dysko RC, Wiggins JE, Wiggins RC. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int 81: 40-55, 2012.
17. Gasser O, Brander C, Wolbers M, Brown NV, Rauch A, Günthard HF, Battegay M, Hess C; Swiss HIV Cohort Study. Expansion of interferon--secreting HIV-specific T cells during successful antiretroviral therapy. HIV Med 14: 241-246, 2013.
18. Genovese G, Friedman DJ, Pollak MR. APOL1 variants and kidney disease in people of recent African ancestry. Nat Rev Nephrol 9: 240-244, 2013.
19. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841-845, 2010.
20. Gulbins E, Kolesnick RN. It takes a CAD to kill a tumor cell with a LMP. Cancer Cell 24: 279-281, 2013.
21. Husain M, Meggs LG, Vashistha H, Simoes S, Griffiths KO, Kumar D, Mikulak J, Mathieson PW, Saleem MA, Del Valle L, Pina-Oviedo S, Wang JY, Seshan SV, Malhotra A, Reiss K, Singhal PC. Inhibition of p66ShcA longevity gene rescues podocytes from HIV-1-induced oxidative stress and apoptosis. J Biol Chem 284: 16648-16658, 2009.
22. Johnstone DB, Shegokar V, Nihalani D, Rathore YS, Mallik L, Ashish Zare V, Ikizler HO, Powar R, Holzman LB. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One 7: e51546, 2012.
23. Kieft R, Capewell P, Turner CM, Veitch NJ, MacLeod A, Hajduk S. Mechanism of Trypanosoma brucei gambiense (group 1) resistance to human trypanosome lytic factor. Proc Natl Acad Sci USA 107: 16137-16141, 2010.
24. Kofman T, Audard V, Narjoz C, Gribouval O, Matignon M, Leibler C, Desvaux D, Lang P, Grimbert P. APOL1 polymorphisms and development of CKD in an identical twin donor and recipient pair. Am J Kidney Dis 63: 816-819, 2014.
25. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol, 22: 2129-2137, 2011.
26. Lan X, Cheng K, Chandel N, Lederman R, Jhaveri A, Husain M, Malhotra A, Singhal PC. High glucose enhances HIV entry into T cells through upregulation of CXCR4. J Leukoc Biol 94: 769-777, 2013.
27. Lan X, Rai P, Chandel N, Cheng K, Lederman R, Saleem MA, Mathieson PW, Husain M, Crosson JT, Gupta K, Malhotra A, Singhal PC. Morphine induces albuminuria by compromising podocyte integrity. PLoS One 8: e55748, 2013.
28. Lan X, Xu J, Kiyota T, Peng H, Zheng JC, Ikezu T. HIV-1 reduces Abeta degrading enzymatic activities in primary human mononuclear phagocytes. J Immunol 186: 6925-6932, 2011.
29. Lecordier L, Vanhollebeke B, Poelvoorde P, Tebabi P, Paturiaux-Hanocq F, Andris F, Lins L, Pays E. C-terminal mutants of apolipoprotein L1 efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS Pathog 5: e1000685, 2009.
30. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB; SK Investigators. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83: 114-120, 2013.
31. Madhavan SM, O'Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 22: 2119-2128, 2011.
32. Medapalli RK, He JC, Klotman PE. HIV-associated nephropathy: pathogenesis. Curr Opin Nephrol Hypertens 20: 306-311, 2011.
33. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 13: 3005-3015, 2002.
34. Oli MW, Cotlin LF, Shiflett AM, Hajduk SL. Serum resistance associated protein blocks lysosomal targeting of trypanosome lytic factor in Trypanosoma brucei. Eukaryotic Cell 5: 132-139, 2006.
35. Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan DP, Pérez-Morga D. The trypanolytic factor of human serum. Nat Rev Microbiol 4: 477-486, 2006.
36. Pérez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homblé F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E. Apolipoprotein LI promotes trypanosome lysis by forming pores in lysosomal membranes. Science 309: 469-472, 2005.
37. Quaggin SE, George AL. Apolipoprotein l1 and the genetic basis for racial disparity in chronic kidney disease. J Am Soc Nephrol 22: 1955-1958, 2011.
38. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11: 1025-1030, 2011.
39. Reiser J, Oh J, Shirato I, Asanuma K, Hug A, Mundel TM, Honey K, Ishidoh K, Kominami E, Kreidberg JA, Tomino Y, Mundel P. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279: 34827-34832, 2004.
40. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13: 630-638, 2002.
41. Sever S, Altintas MM, Nankoe SR, Möller CC, Ko D, Wei C, Henderson J, del Re EC, Hsing L, Erickson A, Cohen CD, Kretzler M, Kerjaschki D, Rudensky A, Nikolic B, Reiser J. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 117: 2095-2104, 2007.
42. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345-350, 2010.
43. US Renal Data System. USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
44. Uzureau P, Uzureau S, Lecordier L, Fontaine F, Tebabi P, Homblé F, Grélard A, Zhendre V, Nolan DP, Lins L, Crowet JM, Pays A, Felu C, Poelvoorde P, Vanhollebeke B, Moestrup SK, Lyngsø J, Pedersen JS, Mottram JC, Dufourc EJ, Pérez-Morga D, Pays E. Mechanism of Trypanosoma brucei gambiense resistance to human serum. Nature 501: 430-434, 2013.
45. Vanhollebeke B, Pays E. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Mol Microbiol 76: 806-814, 2010.
46. Vashistha H, Husain M, Kumar D, Singhal PC. Tubular cell HIV-1 gp120 expression induces caspase 8 activation and apoptosis. Ren Fail 31: 303-312, 2009.
47. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem 283: 21540-21549, 2008.
48. Wasser WG, Tzur S, Wolday D, Adu D, Baumstein D, Rosset S, Skorecki K. Population genetics of chronic kidney disease: the evolving story of APOL1. J Nephrol 25: 603-618, 2012.
49. Zhaorigetu S, Wan G, Kaini R, Jiang Z, Chien-an AH. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 4: 1079-1082, 2008.